Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen

Objective: IRX-2 is a homologous cell-derived multi-cytokine biologic with multifaceted immune modulatory effects that has been shown to induce increased lymphocyte infiltration into primary tumors in oral cavity carcinoma. Our objective was to characterize tumor immune gene expression and epigenomi...

Full description

Bibliographic Details
Main Authors:	Bellile, E. (Author), Bryan Bell, R. (Author), Campos, C.Z (Author), Cernea, C.R (Author), Cruz, F.J.S.M (Author), D'Silva, N. (Author), Erman, A. (Author), Girotto, G.C (Author), Higgins, K. (Author), Kaplan, M. (Author), Kraus, D. (Author), Krempl, G. (Author), Liu, S. (Author), Martins, W.A (Author), McCaul, J. (Author), Moyer, J. (Author), Newman, J. (Author), Nguyen, A. (Author), Nieva, J. (Author), Oliveira, F. (Author), Panwar, A. (Author), Patel, M. (Author), Rozek, L. (Author), Sartor, M.A (Author), the INSPIRE Trial Clinical Investigators (Author), Valentino, J. (Author), Victorina, A.P (Author), Wolf, G.T (Author), Zarins, K. (Author)
Format:	Article
Language:	English
Published:	Elsevier Ltd 2021
Subjects:	adult Article calcium binding protein Calcium-Binding Proteins cancer immunotherapy cell differentiation clinical trial controlled study CpG island cyclophosphamide cytokine Cytokine Cytokines differential gene expression DMBT1 protein, human DNA binding protein DNA methylation DNA-Binding Proteins down regulation female gene expression head and neck cancer Head and Neck Neoplasms head and neck tumor human Humans immune response immune response gene immune-related gene immunity Immunity immunological antineoplastic agent immunotherapy Immunotherapy indometacin IRX 2 keratinization low drug dose lymphocyte count major clinical study male mouth Mouth mouth carcinoma NanoString Neoadjuvant neoadjuvant chemotherapy neoadjuvant therapy Neoadjuvant Therapy omeprazole Oral cavity carcinoma perilymphatic irx 2 cytokine phase 2 clinical trial randomized controlled trial Tumor infiltrating lymphocytes tumor invasion tumor microenvironment tumor suppressor gene tumor suppressor protein Tumor Suppressor Proteins unclassified drug upregulation zinc
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen

Internet

Similar Items